FundingValneva received a new grant from CEPI providing up to $41.3M of additional funding.
PartnershipsValneva announced a new partnership with the Serum Institute of India to supply the vaccine in Asia.
Regulatory ApprovalsIxchiq has received marketing authorization from the Brazilian Health Regulatory Agency for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
Bears Say
Regulatory ChallengesValneva has assumed all further R&D, CMC, and regulatory activities for potential worldwide commercialization of S4V2.
RisksRisks include commercial, regulatory, development, manufacturing, financial/dilution, and liability.
What was Valneva Se’s price range in the past 12 months?
Valneva Se lowest stock price was $3.62 and its highest was $8.66 in the past 12 months.
What is Valneva Se’s market cap?
Valneva Se’s market cap is $499.28M.
When is Valneva Se’s upcoming earnings report date?
Valneva Se’s upcoming earnings report date is Aug 12, 2025 which is in 27 days.
How were Valneva Se’s earnings last quarter?
Valneva Se released its earnings results on May 07, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.278 by $0.138.
What happened to Valneva Se’s price movement after its last earnings report?
Valneva Se reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.278. Following the earnings report the stock price went up 1.698%.
Which hedge fund is a major shareholder of Valneva Se?
Currently, no hedge funds are holding shares in VALN
Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. The company operates primarily in the biotechnology and pharmaceuticals sectors, with a core focus on delivering vaccines for diseases with significant unmet medical needs, including Lyme disease, chikungunya, and COVID-19.